基因智能控股 WGS

Katherine Stueland has served as our Chief Executive Officer and as a member of our Board since April 2022. Ms. Stueland served as President and Chief Executive Officer of GeneDx prior to its acquisition by Sema4 since June 2021. Prior to joining Legacy GeneDx, Ms. Stueland previously served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company from October 2016 to June 2021. Ms. Stueland serves on the Board of Directors for the American Clinical Laboratory Association (ACLA), the national trade association for leading laboratories, advancing policies that improve patient outcomes, expand access to high-quality diagnostics, and enable personalized care. She also serves on the JED Foundation Leadership Council, a nonprofit organization that works to prevent suicide and protect the emotional health of young adults and teens as part of her lifetime commitment to help improve mental health. Ms. Stueland earned a B.S. in English language and literature from Miami University in Ohio.

Kevin Feeley has served as our Chief Financial Officer since August 2022. Mr. Feeley previously served as Senior Vice President of Operations and Head of GeneDx from May 2022 to August 2022. Prior to joining us, Mr. Feeley served as Chief Financial Officer of OPKO Health's diagnostics division from 2016 to 2022, which included BioReference Laboratories, Inc. and Legacy GeneDx, prior to the Acquisition. Mr. Feeley previously served as the U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies. Mr. Feeley is a certified public accountant and holds a BBA from James Madison University.

Bryan Dechairo has served as our Chief Operating Officer since January 2025. Dr. Dechairo previously served as President and Chief Executive Officer of Sherlock Biosciences, Inc., a molecular diagnostics company, from June 2021 to December 2024, and as Officer and Executive Vice President of Development at Myriad Genetics, Inc., a genetic testing and precision medicine company, from August 2017 to April 2021. Dr. Dechairo previously served on the Board of Directors of Biocartis Group NV from March 2023 to December 2024. Dr. Dechairo holds a Ph.D. in Human Genetics from the University College of London and a B.A. in Integrative Biology from the University of California, Berkeley.

Thomas Fuchs, Ph.D., has served as a member of our Board since September 2025. In addition, Dr. Fuchs has served as Eli Lilly and Company's Chief AI Officer since October 2024. Dr. Fuchs previously served as Dean of Artificial Intelligence and Human Health, and the Director of the Hasso Plattner Institute for Digital Health at the Icahn School of Medicine at Mount Sinai from October 2020 to October 2024, where he currently serves as an adjunct professor. Before joining Mount Sinai, Dr. Fuchs was Co-Director of the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center from August 2017 to September 2020 and a professor at Weill Cornell Graduate School of Medical Sciences from 2015 to 2023. He is also a co-founder of Paige.AI, an AI pathology company, where he served as the Chief Scientific Officer from May 2017 to September 2020 and as the Chief Scientist from September 2020 to October 2024. He currently serves on the Board of Paige.AI, a position he has held since May 2017. Dr. Fuchs has previously worked as a research technologist at NASA's Jet Propulsion Laboratory and as a visiting scientist at the California Institute of Technology. Dr. Fuchs holds a Doctor of Sciences (D.Sc.) in Machine Learning from ETH Zurich and a Master's degree in Technical Mathematics from Graz Technical University in Austria.

Joshua Ruch has served as a member of our Board since July 2021 and previously served as the Chairman of our Board from July 2021 to January 2022 and as a member of the board of directors of Legacy Sema4 from November 2017 to July 2021. Mr. Ruch is also a managing partner and co-founder of Rho Capital Partners, an investment and venture capital management company focused on innovative technology, and has held such positions since the founding of Rho Capital Partners in 1981. Prior to co-founding Rho Capital Partners and Rho Ventures in 1981, Mr. Ruch worked as an investment banker at Salomon Brothers in New York, a multinational investment bank. In addition to GeneDx, Mr. Ruch is also a trustee of the Mount Sinai Health System, Carnegie Hall and the National Humanities Center, and is a member of the Board of Governors of the Technion - Israel Institute of Technology and the Steering Committee of the Jacobs Institute. Mr. Ruch received an M.B.A. from the Harvard Business School and a B.S. in electrical engineering from the Technion - Israel Institute of Technology in Haifa, Israel.

Keith Meister has served as a member of our Board since January 2022 and previously served as the Chairman of the Board of CMLS from July 2020 to July 2021. He founded Corvex Management LP, a New York based investment manager, in December 2010 and since its inception has served as its Managing Partner and Chief Investment Officer. From 2003 to 2010, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P., the primary investment vehicle for Carl Icahn. In addition, Mr. Meister previously served as Chairman of CMLS II from December 2020 to September 2021 and CMLS III from January 2021 to December 2021. Mr. Meister also serves on the Board of Directors of MGM Resorts International, a global hospitality and entertainment company, and its affiliate BetMGM; Vestis, a provider of rental uniforms and workplace supplies; and Illumina, Inc., a global leader in DNA sequencing and array-based technologies. Mr. Meister has previously served on the Board of Directors of numerous other public companies in his career, including Yum! Brands Inc., The Williams Companies, Inc., ADT, Inc., Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc.). He is Chairman of the board of the Harlem Children's Zone and also serves on the board of trustees of the American Museum of Natural History. Mr. Meister holds a B.A. degree in government from Harvard College where he graduated cum laude.

Eli Casdin has served as a member of our Board since July 2020 and previously served as the Chief Executive Officer of CM Life Sciences, Inc. from July 2020 to July 2021. Mr. Casdin founded Casdin Capital, LLC, an investment firm focused on the life sciences and healthcare industry in November 2011 and currently serves as its Chief Investment Officer. Mr. Casdin has served on the board of Standard BioTools Inc. since April 2022. Mr. Casdin has also served on the boards of directors of Exact Sciences Corp. from October 2017 to September 2020, Absci Corp. from December 2020 to July 2022, Century Therapeutics, Inc. from February 2021 to October 2022, EQRx, Inc. from January 2020 to November 2022, SomaLogic, Inc., from December 2021 to January 2024 (having previously served as the Chief Executive Officer of CMLS II from December 2020 to September 2021), Tenaya Therapeutics, Inc. from October 2019 to December 2022, and 2seventy Bio, Inc. from March 2024 to May 2025. Mr. Casdin holds an M.B.A. from Columbia Business School and a B.S. degree from Columbia University School of General Studies.

Richard C. Pfenniger, Jr., has served as a member of our Board since April 2022. Mr. Pfenniger is also a private investor who has served as an executive officer of several companies, including as Chief Executive Officer and President of Continucare Corporation, a provider of primary care physician and practice management services, from 2003 until 2011, where he also served as Chairman of the Board of Directors from 2002 until 2011. Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc. from 1997 through 2003. Prior to joining Whitman, he served as the Chief Operating Officer of IVAX Corporation, a pharmaceutical company, from 1994 to 1997, and, from 1989 to 1994, he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a director of OPKO Health, Inc., a biopharmaceutical and medical diagnostics company; Cocrystal Pharma, Inc., a development stage pharmaceutical company; and Fluent, Inc., a data driven performance marketing company. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. Mr. Pfenniger previously served as a director of Ivax Corporation; Asensus Surgical, Inc., a medical device company; BioCardia, Inc., clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases; and GP Strategies Corporation, a corporate education and training company.

On June 16, 2026, GeneDx Holdings Corp announced the appointment of Mark Gardner, in the role of President, which was effective on June 15, 2026. Prior to joining the Company, Mr. Gardner served as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics Incorporated, from September 2022 to June 2026. Mr. Gardner also held executive leadership roles at prominent diagnostic and life sciences companies, including at Corza Medical Inc., where he was Executive Partner, Senior Vice President and General Manager of European Commercial Operations and Biosurgery Products from June 2019 to October 2022, at OmniSeq Corporation, where he was Chief Executive Officer, and at Thermo Fisher Scientific Inc., where he held Vice President and General Manager positions. Mr. Gardner holds a B.S. in History from the United States Naval Academy, an M.A. in National Security Studies from Georgetown University, and an M.B.A. from The Wharton School of the University of Pennsylvania. Life Technologies, where he led global genomics, sequencing and life sciences businesses.